Apollo Therapeutics and Sunshine Lake Pharma have signed a license deal for APL-18881, a bi-specific fusion protein targeting ...

Sino-American firm Insilico Medicine has shown the potential not just of its pipeline and lead candidate by presenting ...

Although it is seeing a downturn in sales and profits, German biotech BioNTech (Nasdaq: BNTX) is continuing to acquire assets ...

Cambridge, USA-based Vesalius Therapeutics has entered into a multi-target strategic alliance with the UK’s GSK to discover ...

Lundbeck’s Q3 2024 revenue rose 18% to $815 million, driven by strategic brands like Vyepti and Rexulti in the USA. Vyepti’s ...

Physics-based US software specialist Schrödinger’s shares leapt nearly 14% to $22.25 on the back of news that it has entered ...

Syndax Pharmaceuticals (Nasdaq: SNDX) has announced that its Phase II AUGMENT-101 trial of experimental drug revumenib ...

Gilead Sciences has announced new data from its pivotal Phase III PURPOSE 2 trial providing further details on the efficacy, ...

Shares of US genetic meds company MeiraGTx Holdings were up 7% at $7.12 in early trading after it announced important ...

New York, USA-based rare neurological disease drug developer Neurogene has announced positive interim clinical data in the first four participants in the low-dose cohort of its ongoing Phase I/II open ...

Japanese drugmaker Nippon Shinyaku and USA-based Atsena Therapeutics have entered into an exclusive license agreement for the ...

US biotech major Amgen closed 7% lower on Tuesday after investors questioned whether reductions in bone mineral density might be linked to the use of its investigational obesity candidate MariTide ...